Additionally, Long et al. reported that BRAF/MEK combination therapy provided durable responses in patients with metastatic ALM, highlighting the potential of this targeted treatment strategy for advanced disease [52]. This evidence concerns the gene MAP2K7 and acral lentiginous melanoma.